Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11119714 | 0.83 | MTNR1B (0.56) | MTNR1BACETP53HDAC3HDAC1 | |
| SCHEMBL3609218 | 0.82 | ACE (0.70) | MTNR1BACEHDAC3HDAC1HDAC10 | |
| SCHEMBL16017669 | 0.80 | MAPK1 (0.65) | MAPK1 | |
| SCHEMBL17558824 | 0.78 | MTNR1B (0.54) | MTNR1BACEMAPK1 | |
| SCHEMBL30605435 | 0.77 | CHRM3 (0.58) | MTNR1BCYP2D6 | |
| SCHEMBL3612165 | 0.77 | ACE (0.50) | MTNR1BACE | |
| SCHEMBL22494094 | 0.77 | ACE (0.61) | MTNR1BACE | |
| SCHEMBL11816884 | 0.75 | MTNR1B (0.57) | MTNR1BTP53OPRM1OPRK1OPRD1 | |
| SCHEMBL22525292 | 0.75 | ACE (0.59) | MTNR1BACE | |
| SCHEMBL9541988 | 0.75 | OPRM1 (0.53) | HDAC3HDAC1OPRM1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-06-06 | — | — | US | disclosed |
| US-6468971-B1 | Maintaining kidney function during surgery or trauma | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2002-10-22 | — | — | US | disclosed |
| EP-1244738-A1 | BIOMIMETIC SILICONE ELASTOMERS | Xiomateria Limited (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001034695-A1 | BIOMIMETIC SILICONE ELASTOMERS | XIOMATERIA LIMITED (GB) | 2001-05-17 | — | — | WO | disclosed |
| US-5859043-A | Method for maintaining kidney function during surgery or severe trauma under general anesthesia | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | OPRK1, OPRL1, OPRM1 | MTNR1B 54/4885ACE 199/4885TP53 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.